MEDICINE DETAILS
Venclyxto
Active ingredient: Venclexta Venetoclax
Neutral reference profile for an independent medicine-access consultancy enquiry about Venclyxto (Venclexta Venetoclax). No medicine is offered for sale.
NEXT STEP
Choose the strength and pack
✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Venclyxto used for?
Venclexta/Venclyxto (venetoclax) is a B-Cell lymphoma-2 (BCL-2) inhibitor (chemotherapy) indicated for the treatment of adults with:
- Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- Newly-diagnosed acute myeloid leukemia (AML) in combination with azacitidine, or decitabine, or low-dose cytarabine, who:
- are 75 years of age or older, or
- have other medical conditions that prevent the use of standard chemotherapy.
It is indicated as monotherapy for the treatment of people with chronic lymphocytic leukemia (CLL), with or without the 17p deletion, who have received at least one prior therapy. The presence of 17p deletion can be assessed using specifically designed diagnostic tools.
Venclexta/Venclyxto (venetoclax) in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy. Venetoclax is marketed in the USA, Canada, and Australia under the name Venclexta, and in the European Union under the name Venclyxto.
It is available in tablet form, each containing either 10mg, 50mg, or 100mg of venetoclax.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Venclyxto identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
-
10 mg · 14 tablets Catalogue organisation: AbbVie Deutschland GmbH & Co. KG
-
50 mg · 7 tablets Catalogue organisation: AbbVie Deutschland GmbH & Co. KG
-
100 mg · 7 tablets Catalogue organisation: AbbVie Deutschland GmbH & Co. KG
-
100 mg · 14 tablets Catalogue organisation: AbbVie Deutschland GmbH & Co. KG
-
100 mg · 112 tablets Catalogue organisation: AbbVie Deutschland GmbH & Co. KG
-
100 mg · 360 tablets Catalogue organisation: AbbVie Deutschland GmbH & Co. KG
OFFICIAL SOURCES
Check the Venclyxto record at an official source.
Search for “Venclyxto” or “Venclexta Venetoclax”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Venclyxto.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Venclyxto
01What is Venclyxto?＋
This directory record associates the brand name Venclyxto with the active ingredient Venclexta Venetoclax. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Venclyxto strengths and packs are recorded?＋
The catalogue currently shows: 10 mg · 14 tablets; 50 mg · 7 tablets; 100 mg · 7 tablets; 100 mg · 14 tablets. Check the complete strength, dosage form and pack description against the prescription and medicine box.
03Who manufactures Venclyxto?＋
Catalogue records currently name: AbbVie Deutschland GmbH & Co. KG. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Venclyxto?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Venclyxto, payment request, stock guarantee or binding offer.
06Can I buy Venclyxto from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.